Advancing TIL Therapy Through Neoantigen-Guided Selection of Tumor- Reactive T-Cells

• Leveraging patient-specific neoantigens to identify and enrich functional tumorreactive T-cells
• Overcoming low frequencies of tumor-reactive lymphocytes in non-melanoma solid tumors
• Establishing a framework for next-generation, precision TIL manufacturing

Speakers:

Nicholas Restifo

Chief Medical Officer

Medici Therapeutics